| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Analytical control strategies for mutagenic impurities: Current challenges and future opportunities?
|
Teasdale, Andrew
|
|
2018
|
101 |
C |
p. 66-84
|
article
|
| 2 |
Critical review of reports on impurity and degradation product profiling in the last decade
|
Görög, Sándor
|
|
2018
|
101 |
C |
p. 2-16
|
article
|
| 3 |
Critical review on establishment and availability of impurity and degradation product reference standards, challenges faced by the users, recent developments, and trends
|
Singh, Dilip Kumar
|
|
2018
|
101 |
C |
p. 85-107
|
article
|
| 4 |
Editorial Board
|
|
|
2018
|
101 |
C |
p. ii
|
article
|
| 5 |
Identification, analysis and safety assessment of leachables and extractables
|
Jenke, Dennis
|
|
2018
|
101 |
C |
p. 56-65
|
article
|
| 6 |
Impact and practicability of recently introduced requirements on elemental impurities
|
Pohl, Pawel
|
|
2018
|
101 |
C |
p. 43-55
|
article
|
| 7 |
Impurity investigations by phases of drug and product development
|
Olsen, Bernard A.
|
|
2018
|
101 |
C |
p. 17-23
|
article
|
| 8 |
Measurement of impurities to support process development and manufacture of biopharmaceuticals
|
Oshinbolu, Sheun
|
|
2018
|
101 |
C |
p. 120-128
|
article
|
| 9 |
‘Quality by Design’ approach for the analysis of impurities in pharmaceutical drug products and drug substances
|
Dispas, Amandine
|
|
2018
|
101 |
C |
p. 24-33
|
article
|
| 10 |
Reactive impurities in large and small molecule pharmaceutical excipients – A review
|
Zhang, Kelly
|
|
2018
|
101 |
C |
p. 34-42
|
article
|
| 11 |
State-of-the-art and trends for the SI traceable value assignment of the purity of peptides using the model compound angiotensin I
|
Josephs, Ralf D.
|
|
2018
|
101 |
C |
p. 108-119
|
article
|
| 12 |
The last decade in regulation and control of impurities in pharmaceuticals
|
Singh, Saranjit
|
|
2018
|
101 |
C |
p. 1
|
article
|
Journal description